Azithromycin versus erythromycin for community-acquired pneumonia: A cost-minimization analysis

American Journal of Health-System Pharmacy

Volumn 56, Issue 15, 1999, Pages 1521-1524

  Howard, Kimberly B ^a,b   Blumenschein, Karen ^d   Rapp, Robert P ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d NONE

Author keywords

Azithromycin; Costs; Drug comparisons; Economics; Erythromycin; Injections; Macrofides; Pneumonia; Toxicity

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; COST; COST MINIMIZATION ANALYSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MEDICAL RECORD; NURSING; PAIN; PHARMACY; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0033179846     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.15.1521     Document Type: Article

References (10)

1. Niederman MS, Bass JB, Campbell GD et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993; 148:1418-26.
2. Niederman MS. ATS guidelines for treatment of community-acquired pneumonia. Infect Med. 1994; 11:763-4,785-90.
3. Bartlett JG, Breiman RF, Mandell LA et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis. 1998; 26:811-38.
4. Marlin GE, Thompson PJ, Jenkins CR et al. Study of serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection. Hum Toxicol. 1983; 2:593-605.
5. Zithromax package insert. New York: Pfizer Laboratories; 1997.
6. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991; 91(S3A):40S-45S.
7. Hitt CM, Nightingale CH, Quintilliani R et al. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime. Am J Health-Syst Phann. 1997; 54: 1614-8.
8. Garrelts JC, Horst WD, Silkey B et al. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy. 1994; 14:438-45.
9. Mithani H, Brown G. The economic impact of once-daily versus conventional administration of gentamicin and tobramycin. Pharmacoeconomics. 1996; 10:494-503.
10. McEvoy GK, ed. AHFS drug information 98. Bethesda, MD: American Society of Health-System Pharmacists; 1998.